Literature DB >> 29565004

End of the road for daclizumab in multiple sclerosis.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29565004     DOI： 10.1016/S0140-6736(18)30565-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis.

Authors:  Babak Soleimani; Katy Murray; David Hunt
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.606

Review 2.  Drug-Induced Liver Injury: Highlights of the Recent Literature.

Authors:  Mark Real; Michele S Barnhill; Cory Higley; Jessica Rosenberg; James H Lewis
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

3.  Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study.

Authors:  Ralf Gold; Ernst-Wilhelm Radue; Gavin Giovannoni; Krzysztof Selmaj; Eva Kubala Havrdova; Xavier Montalban; Dusan Stefoski; Till Sprenger; Randy R Robinson; Sami Fam; Jonathan Smith; Spyros Chalkias; Giorgio Giannattasio; Gabriel Lima; Wanda Castro-Borrero
Journal:  J Neurol       Date:  2020-05-25       Impact factor: 4.849

Review 4.  Potential application of hydrogel to the diagnosis and treatment of multiple sclerosis.

Authors:  Haochuan Liu; Bing Chen; Qingsan Zhu
Journal:  J Biol Eng       Date:  2022-04-08       Impact factor: 4.355
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.